3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Neoplasm Metastasis
3
Philadelphia Chromosome
2
Ovarian Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia
2
Sarcoma
1
Recurrence
1
Peritoneal Neoplasms
1
Neoplasm, Residual
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Genital Neoplasms, Female
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Breast Neoplasms
1
Blast Crisis
1
Appendiceal Neoplasms
1
Interventions
pembrolizumab
57
Nivolumab
50
Ipilimumab
31
Specimen Handling
23
Magnetic Resonance Spectroscopy
19
Cyclophosphamide
14
Biopsy
11
fludarabine
10
binimetinib
10
Opdualag
10
trametinib
9
relatlimab
9
Radiosurgery
9
CTLA-4 Antigen
9
dabrafenib
8
lifileucel
7
fludarabine phosphate
7
aldesleukin
7
encorafenib
6
Interleukin-2
6
cemiplimab
5
atezolizumab
5
Paclitaxel
5
Blood Specimen Collection
5
X-Rays
4
Taxes
4
Pemetrexed
4
Gemcitabine
4
Cisplatin
4
Carboplatin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Melanoma
×
nilotinib
×
90 days
×
Clear all
No trials found.